TREOSULFAN

Treosulfan Adverse Events Reported to the FDA Over Time

How are Treosulfan adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Treosulfan, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Treosulfan is flagged as the suspect drug causing the adverse event.

Most Common Treosulfan Adverse Events Reported to the FDA

What are the most common Treosulfan adverse events reported to the FDA?

Graft Versus Host Disease	28 (4.12%)
Convulsion	24 (3.53%)
Acute Graft Versus Host Disease	22 (3.24%)
Cytomegalovirus Infection	20 (2.95%)
Multi-organ Failure	18 (2.65%)
Pneumonitis	16 (2.36%)
Adenovirus Infection	14 (2.06%)
Acute Graft Versus Host Disease In ...	13 (1.91%)
Chronic Graft Versus Host Disease	13 (1.91%)
Epstein-barr Virus Infection	13 (1.91%)
Rash	12 (1.77%)
	Show More
Hypertension	11 (1.62%)
Mucosal Inflammation	11 (1.62%)
Adenoviral Hepatitis	9 (1.33%)
Evans Syndrome	9 (1.33%)
Nephrotic Syndrome	8 (1.18%)
Sepsis	8 (1.18%)
Acute Graft Versus Host Disease In ...	7 (1.03%)
Cerebral Haemorrhage	7 (1.03%)
Pyrexia	7 (1.03%)
Renal Failure	7 (1.03%)
Acute Graft Versus Host Disease In ...	6 (.88%)
Blood Bilirubin Increased	6 (.88%)
Capillary Leak Syndrome	6 (.88%)
Human Herpesvirus 6 Infection	6 (.88%)
Pulmonary Haemorrhage	6 (.88%)
Respiratory Failure	6 (.88%)
Toxic Encephalopathy	6 (.88%)
Toxic Epidermal Necrolysis	6 (.88%)
C-reactive Protein Increased	5 (.74%)
Cardiac Failure	5 (.74%)
Death	5 (.74%)
Pericarditis	5 (.74%)
Platelet Count Decreased	5 (.74%)
Venoocclusive Liver Disease	5 (.74%)
Cholestasis	4 (.59%)
Depression Suicidal	4 (.59%)
Disease Progression	4 (.59%)
Drug Toxicity	4 (.59%)
Febrile Neutropenia	4 (.59%)
Fungal Infection	4 (.59%)
Gastroenteritis Viral	4 (.59%)
Herpes Zoster	4 (.59%)
Hypertonia	4 (.59%)
Optic Neuritis	4 (.59%)
Pancytopenia	4 (.59%)
Retinitis	4 (.59%)
Septic Shock	4 (.59%)
Staphylococcal Skin Infection	4 (.59%)
Tracheostomy	4 (.59%)
Venoocclusive Disease	4 (.59%)
Candidiasis	3 (.44%)
Cholecystitis	3 (.44%)
Haemoglobin Decreased	3 (.44%)
Hepatic Encephalopathy	3 (.44%)
Hepatorenal Syndrome	3 (.44%)
Lymphoproliferative Disorder	3 (.44%)
Neurological Decompensation	3 (.44%)
Pain	3 (.44%)
Pancreatitis Necrotising	3 (.44%)
Paraparesis	3 (.44%)
Paroxysmal Arrhythmia	3 (.44%)
Peritonitis Bacterial	3 (.44%)
Pneumonia	3 (.44%)
Pulmonary Hypertension	3 (.44%)
Staphylococcal Scalded Skin Syndrom...	3 (.44%)
Stupor	3 (.44%)
Subarachnoid Haemorrhage	3 (.44%)
Thrombocytopenia	3 (.44%)
Vanishing Bile Duct Syndrome	3 (.44%)
Abdominal Pain	2 (.29%)
Acute Myeloid Leukaemia	2 (.29%)
Acute Respiratory Failure	2 (.29%)
Anaphylactic Shock	2 (.29%)
Anuria	2 (.29%)
Arrhythmia Supraventricular	2 (.29%)
Bacterial Infection	2 (.29%)
Blood Amylase Increased	2 (.29%)
Blood Creatinine Increased	2 (.29%)
Bone Marrow Failure	2 (.29%)
Bronchopulmonary Aspergillosis	2 (.29%)
Central Nervous System Infection	2 (.29%)
Cerebral Infarction	2 (.29%)
Complications Of Bone Marrow Transp...	2 (.29%)
Constipation	2 (.29%)
Cystitis Haemorrhagic	2 (.29%)
Dehydration	2 (.29%)
Diabetes Mellitus	2 (.29%)
Disease Recurrence	2 (.29%)
Dizziness	2 (.29%)
Drug Ineffective	2 (.29%)
Dyspnoea	2 (.29%)
Ear Infection	2 (.29%)
Ear Infection Bacterial	2 (.29%)
Engraftment Syndrome	2 (.29%)
Epstein-barr Virus Associated Lymph...	2 (.29%)
Erythema	2 (.29%)
Eye Infection Fungal	2 (.29%)
Fatigue	2 (.29%)
Fungus Serology Test Positive	2 (.29%)
Fusarium Infection	2 (.29%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Treosulfan, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Treosulfan is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Treosulfan

What are the most common Treosulfan adverse events reported to the FDA?

Immune	94 (13.84%)
Viral Infectious	75 (11.05%)
Infections - Pathogen Unspecified	27 (3.98%)
Epidermal And Dermal Conditions	25 (3.68%)
Seizures	24 (3.53%)
Lower Respiratory Tract Disorders	23 (3.39%)
Hepatic And Hepatobiliary	21 (3.09%)
Bacterial Infectious	19 (2.8%)
Respiratory	18 (2.65%)
Fungal Infectious	17 (2.5%)
Central Nervous System Vascular	14 (2.06%)
	Show More
Hepatobiliary	14 (2.06%)
Nephropathies	11 (1.62%)
Renal Disorders	11 (1.62%)
Vascular Hypertensive	11 (1.62%)
Hematology Investigations	10 (1.47%)
Encephalopathies	9 (1.33%)
Hemolyses And Related Conditions	9 (1.33%)
Neurological	9 (1.33%)
Procedural And Device Related Injur...	9 (1.33%)
White Blood Cell	8 (1.18%)
Anemias Nonhemolytic And Marrow Dep...	7 (1.03%)
Body Temperature Conditions	7 (1.03%)
Gastrointestinal Signs	7 (1.03%)
Leukemias	7 (1.03%)
Cardiac Arrhythmias	6 (.88%)
Decreased And Nonspecific Blood Pre...	6 (.88%)
Hematopoietic Neoplasms	6 (.88%)
Bile Duct	5 (.74%)
Chemical Injury And Poisoning	5 (.74%)
Fatal Outcomes	5 (.74%)
Heart Failures	5 (.74%)
Pericardial	5 (.74%)
Protein And Chemistry Analyses	5 (.74%)
Allergic Conditions	4 (.59%)
Cranial Nerve Disorders	4 (.59%)
Depressed Mood Disorders	4 (.59%)
Movement Disorders	4 (.59%)
Myocardial	4 (.59%)
Neuromuscular	4 (.59%)
Ocular Infections, Irritations And ...	4 (.59%)
Respiratory Tract Therapeutic Proce...	4 (.59%)
Vascular	4 (.59%)
Exocrine Pancreas Conditions	3 (.44%)
Gallbladder	3 (.44%)
Hematological And Lymphoid Tissue T...	3 (.44%)
Microbiology And Serology	3 (.44%)
Platelet	3 (.44%)
Pulmonary Vascular	3 (.44%)
Therapeutic Procedures And Supporti...	3 (.44%)
Bladder And Bladder Neck Disorders	2 (.29%)
Electrolyte And Fluid Balance Condi...	2 (.29%)
Gastrointestinal	2 (.29%)
Gastrointestinal Hemorrhages	2 (.29%)
Gastrointestinal Motility And Defec...	2 (.29%)
Gastrointestinal Therapeutic Proced...	2 (.29%)
Glucose Metabolism Disorders	2 (.29%)
Immunology And Allergy	2 (.29%)
Metabolic And Nutritional Disorders...	2 (.29%)
Peripheral Neuropathies	2 (.29%)
Renal And Urinary Tract Investigati...	2 (.29%)
Reproductive Neoplasms Male Maligna...	2 (.29%)
Therapeutic And Nontherapeutic Effe...	2 (.29%)
Arteriosclerosis, Stenosis, Vascula...	1 (.15%)
Breast	1 (.15%)
Cardiac Disorder Signs	1 (.15%)
Congenital And Hereditary	1 (.15%)
Gastrointestinal Conditions	1 (.15%)
Head And Neck Therapeutic Procedure...	1 (.15%)
Hematological	1 (.15%)
Metabolic, Nutritional And Blood Ga...	1 (.15%)
Metastases	1 (.15%)
Miscellaneous And Site Unspecified ...	1 (.15%)
Musculoskeletal And Connective Tiss...	1 (.15%)
Pleural	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Treosulfan, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Treosulfan is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.